Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides. 2025 to 2029

List of Tables

Report Overview:

Are cures for cancer in sight? What is the opportunity in this market? What companies are poised to benefit? Is disruption a possibility? Find out in this comprehensive report.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. CAR - T Cells? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon.

Already worth billions the global market is poised for dramatic growth. The impact on the health care industry is enormous. The report forecasts the market size out to 2027.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

1. Market Guides

1.1. Situation Analysis
1.2. Guide for Executives and Marketing Staff
1.3. Guide for Investment Analysts and Management Consultants

2. Introduction and Market Definition

2.1. What is Cancer Immunotherapy?
2.2. Immunotherapy - the looming cures
2.3. Market Definition
- 2.3.1. Market Size
- 2.3.2. Currency
- 2.3.3. Years
2.4. Methodology
- 2.4.1. Methodology
- 2.4.2. Sources
- 2.4.3. Authors
2.5. U.S. Medical Market and Pharmceutical Spending - Perspective
- 2.5.1. Global Expenditures for Medicines

3. Immunotherapy - Guide to Immune Technologies

3.1. The Immune System
- 3.1.1. Innate immune system
  - 3.1.1.1. Surface barriers
  - 3.1.1.2. Inflammation
  - 3.1.1.3. Complement system
  - 3.1.1.4. Cellular barriers
  - 3.1.1.5. Natural killer cells
- 3.1.2. Adaptive immune system
  - 3.1.2.1. Lymphocytes
  - 3.1.2.2. Killer T cells
  - 3.1.2.3. Helper T cells
  - 3.1.2.4. Gamma delta T cells
  - 3.1.2.5. B lymphocytes and antibodies
- 3.1.3. Tumor immunology - the immune surveillance system
3.2. Immuno Oncology Technologies
- 3.2.1. Monoclonal Antibodies
  - 3.2.1.1. Outlook for Monoclonal Antibodies
  - 3.2.1.2. Companies with Monoclonal Antibodies in their Pipeline
- 3.2.2. Cancer vaccines
  - 3.2.2.1. Outlook for Cancer Vaccines
  - 3.2.2.2. Companies with Cancer Vaccines in their Pipeline
- 3.2.3. Cytokines
  - 3.2.3.1. Outlook for Cytokines
  - 3.2.3.2. Companies with Cytokines in their Pipeline
- 3.2.4. Cell Based Therapies
  - 3.2.4.1. Outlook for Cell Based Therapies
  - 3.2.4.2. Companies with Cell Based Therapies in their Pipeline
- 3.2.5. Inhibitors/Agonists
  - 3.2.5.1. Outlook for Inhibitors/Agonists
  - 3.2.5.2. Companies with Inhibitors/Agonists in their Pipeline
- 3.2.6. Antibody Drug Conjugates
  - 3.2.6.1. Outlook for Antibody Drug Conjugates
  - 3.2.6.2. Companies with Antibody Drug Conjugates in their Pipeline
- 3.2.7. Others
  - 3.2.7.1. Outlook for Other Therapeutics
  - 3.2.7.2. Companies with Viral Therapeutics in their Pipeline
  - 3.2.7.3. Companies with Other Therapeutics in their Pipeline

4. Industry Overview

4.1. Market Players - Roles & Impacts
- 4.1.1. Drug manufacturers - Larger/pharmaceutical
- 4.1.2. Drug manufacturers - Generic
- 4.1.3. Contract Research and Manufacturing
- 4.1.4. In Vitro Diagnostics Industry
- 4.1.5. Drug Marketing Companies
- 4.1.6. Biotechnology Companies
- 4.1.7. Regulatory Bodies

5. Market Trends

5.1. Factors Driving Growth
- 5.1.1. Outcome potential
- 5.1.2. Fast tracking
- 5.1.3. Funding
- 5.1.4. Technology Environment
- 5.1.5. Target Solutions
5.2. Factors Limiting Growth
- 5.2.1. Cost of Treatment
- 5.2.2. Clinical Trials Role
- 5.2.3. Combinations
- 5.2.4. Protocols
5.3. Therapeutic Technology Development
- 5.3.1. Combinations - Issues and Complexity
- 5.3.2. Preference for a drug
- 5.3.3. Problems of Immunity Engineering
- 5.3.4. The Role of Cost
- 5.3.5. The Disruption Dynamic
- 5.3.6. CAR-T Cell Therapy
- 5.3.7. The Next Five Years

6. Cancer Immunotherapy Recent Developments

6.1. Recent Developments - Importance and How to Use This Section
- 6.1.1. Importance of These Developments
- 6.1.2. How to Use This Section
6.2. Merck, buys into new kind of cancer immunotherapy
6.3. Immunotherapy after surgery
6.4. Anti-CTLA-4 nanobody a promising approach
6.5. Continued Success with Immunotherapy in Melanoma
6.6. AC Immune Receives FDA Fast Track Designation
6.7. LTZ Announces Financing
6.8. Immunotherapy for Cancer Overview
6.9. Implantable device shrinks pancreatic tumors
6.10. mRNA Vaccine And Immunotherapy Reduce Melanoma Recurrence
6.11. Towards a Universal Cancer Immunotherapy
6.12. New Strategy May Improve T-Cell Therapy in Solid Tumors
6.13. Immunotherapy linked to increase in Medicare spending
6.14. Immunotherapy Effective with Ovarian Cancer
6.15. Cancer Immunotherapy Granted Fast Track

7. Profiles of Key Immunotherapy Companies

7.1. AbbVie
7.2. Achilles Therapeutics
7.3. Acumen Pharmaceuticals
7.4. Adagene
7.5. Adaptimmune Therapeutics
7.6. Adicet Bio
7.7. ALX Oncology Holdings
7.8. Ambrx Biopharma
7.9. Amgen
7.10. Apexigen
7.11. Arcus Biosciences
7.12. argenx
7.13. AstraZeneca
7.14. Atreca
7.15. Avalo Therapeutics
7.16. Avid Bioservices
7.17. Bavarian Nordic
7.18. BioAtla
7.19. Biogen Inc.
7.20. BioNTech
7.21. Bolt Biotherapeutics
7.22. Bristol-Myers Squibb
7.23. Candel Therapeutics
7.24. Caribou Biosciences
7.25. Celldex Therapeutics
7.26. Checkpoint Therapeutics
7.27. Chinook Therapeutics
7.28. Corvus Pharmaceuticals
7.29. Cullinan Oncology
7.30. Eli Lilly
7.31. EOM Pharmaceuticals
7.32. Evaxion Biotech
7.33. Genenta Science
7.34. Gilead Sciences
7.35. Gracell Biotechnologies
7.36. Greenwich LifeSciences
7.37. Gritstone bio
7.38. Harpoon Therapeutics
7.39. ImmunityBio
7.40. Immunocore Holdings
7.41. Immunome
7.42. IMV Inc
7.43. Incyte
7.44. Indaptus Therapeutics
7.45. Instil Bio
7.46. Iovance Biotherapeutics
7.47. Johnson & Johnson
7.48. Marker Therapeutics
7.49. Medicenna Therapeutics
7.50. Merck & Co.
7.51. Merus
7.52. Moderna
7.53. Mustang Bio
7.54. Nanobiotix
7.55. Neoleukin Therapeutics
7.56. Novartis
7.57. Novavax
7.58. Oncorus
7.59. PDS Biotechnology
7.60. Pfizer
7.61. Regeneron Pharmaceuticals
7.62. Roche
7.63. Sanofi
7.64. Sensei Biotherapeutics
7.65. Senti Biosciences
7.66. Surface Oncology
7.67. Takeda Pharmaceutical
7.68. TC Biopharm
7.69. ThermoGenesis Holdings
7.70. UroGen Pharma
7.71. Werewolf Therapeutics
7.72. Xilio Therapeutics
7.73. Zymeworks

8. The Global Market for Immuno-Oncology Therapeutics

8.1. Global Market Overview by Country
- 8.1.1. Table - Global Market by Country
- 8.1.2. Chart - Global Market by Country
8.2. Global Market by Therapy - Overview
- 8.2.1. Table - Global Market by Therapy
- 8.2.2. Chart - Global Market by Therapy - Base/Final Year Comparison
- 8.2.3. Chart - Global Market by Therapy - Base Year
- 8.2.4. Chart - Global Market by Therapy - End Year
- 8.2.5. Chart - Global Market by Therapy - Share by Year
- 8.2.6. Chart - Global Market by Therapy - Segments Growth
8.3. Global Market by Cancer - Overview
- 8.3.1. Table - Global Market by Cancer
- 8.3.2. Chart - Global Market by Cancer - Base/Final Year Comparison
- 8.3.3. Chart - Global Market by Cancer - Base Year
- 8.3.4. Chart - Global Market by Cancer - End Year
- 8.3.5. Chart - Global Market by Cancer - Share by Year
- 8.3.6. Chart - Global Market by Cancer - Segments Growth
8.4. Global Market by Customer - Overview
- 8.4.1. Table - Global Market by Customer
- 8.4.2. Chart - Global Market by Customer - Base/Final Year Comparison
- 8.4.3. Chart - Global Market by Customer - Base Year
- 8.4.4. Chart - Global Market by Customer - End Year
- 8.4.5. Chart - Global Market by Customer - Share by Year
- 8.4.6. Chart - Global Market by Customer - Segments Growth

9. Global Immuno-Oncology Therapy Markets - By Therapy

9.1. MAB
- 9.1.1. Table MAB - by Country
- 9.1.2. Chart - MAB Growth
9.2. Cytokine
- 9.2.1. Table Cytokine - by Country
- 9.2.2. Chart - Cytokine Growth
9.3. Vaccine
- 9.3.1. Table Vaccine - by Country
- 9.3.2. Chart - Vaccine Growth
9.4. Cell Based
- 9.4.1. Table Cell Based - by Country
- 9.4.2. Chart - Cell Based Growth
9.5. Inhibitor/Agonist
- 9.5.1. Table Inhibitor/Agonist - by Country
- 9.5.2. Chart - Inhibitor/Agonist Growth
9.6. Other IO Therapy
- 9.6.1. Table Other IO Therapy - by Country
- 9.6.2. Chart - Other IO Therapy Growth

10. Global Immuno-Oncology Therapeutic Markets - By Cancer

10.1. Breast
- 10.1.1. Table Breast - by Country
- 10.1.2. Chart - Breast Growth
10.2. ColoRectal
- 10.2.1. Table ColoRectal - by Country
- 10.2.2. Chart - ColoRectal Growth
10.3. Cervical
- 10.3.1. Table Cervical - by Country
- 10.3.2. Chart - Cervical Growth
10.4. Lung
- 10.4.1. Table Lung - by Country
- 10.4.2. Chart - Lung Growth
10.5. Precancer
- 10.5.1. Table Precancer - by Country
- 10.5.2. Chart - Precancer Growth
10.6. Prostate
- 10.6.1. Table Prostate - by Country
- 10.6.2. Chart - Prostate Growth
10.7. Melanoma
- 10.7.1. Table Melanoma - by Country
- 10.7.2. Chart - Melanoma Growth
10.8. Blood
- 10.8.1. Table Blood - by Country
- 10.8.2. Chart - Blood Growth
10.9. Other Cancer
- 10.9.1. Table Other Cancer - by Country
- 10.9.2. Chart - Other Cancer Growth

11. Global Immuno-Oncology Therapeutic Markets - By Customer

11.1. Pharma
- 11.1.1. Table Pharma - by Country
- 11.1.2. Chart - Pharma Growth
11.2. Clinic
- 11.2.1. Table Clinic - by Country
- 11.2.2. Chart - Clinic Growth
11.3. Other Customer
- 11.3.1. Table Other Customer - by Country
- 11.3.2. Chart - Other Customer Growth

12. Appendices

12.1. FDA Cancer Drug Approvals by Year
12.2. Clinical Trials Started
12.3. Prevalence of Cancer Treatments

Table of Tables

Table 1: List of Cancers by Mortality
Table 2: Overview of Innate and Adaptive Immunity
Table 3: Approval Rates of Therapeutic Antibodies
Table 4: Monoclonal Antibody Companies
Table 5: Cancer Vaccine Companies
Table 6: Cytokine Companies
Table 7: Cell Based Therapy Companies
Table 8: Inhibitor/Agonist Companies
Table 9: Antibody Drug Conjugate Companies
Table 10: Viral Therapeutics Companies
Table 11: Other Therapeutics Companies
Table 12: Market Players by Type
Table 13: Five Factors Driving Growth
Table 14: Four Factors Limiting Growth
Table 15 - Global Market by Region
Table 16: Global Market by Therapy
Table 17: Global Market by Cancer
Table 18: Global Market by Customer
Table 19: MAB by Country
Table 20: Cytokine by Country
Table 21: Vaccine by Country
Table 22: Cell Based by Country
Table 23: Inhibitor/Agonist by Country
Table 24: Other IO Therapy by Country
Table 25: Breast by Country
Table 26: ColoRectal by Country
Table 27: Cervical by Country
Table 28: Lung by Country
Table 29: Precancer by Country
Table 30: Prostate by Country
Table 31: Melanoma by Country
Table 32: Blood by Country
Table 33: Other Cancer by Country
Table 34: Pharma by Country
Table 35: Clinic by Country
Table 36: Other Customer by Country

Table of Figures

Figure 1: Medicine Expenditures Perspective
Figure 2: Helper T Cell Roles
Figure 3: Antibody Diagram
Figure 4: Macrophages attack a Cancer Cell
Figure 5: CAR-T Clinical Trials
Figure 6: Antibody Drug Conjugate Diagram
Figure 7: Growth rates of IO Therapies
Figure 8: Global Market Pareto Chart
Figure 9: Global Market by Therapy - Base vs. Final
Figure 10: Global Market by Therapy Base Year
Figure 11: Global Market by Therapy End Year
Figure 12: Therapy Share by Year
Figure 13: Therapy Segments Growth
Figure 14: Global Market by Cancer - Base vs. Final
Figure 15: Global Market by Cancer Base Year
Figure 16: Global Market by Cancer End Year
Figure 17: Cancer Share by Year
Figure 18: Cancer Segments Growth
Figure 19: Global Market by Customer - Base vs. Final
Figure 20: Global Market by Customer Base Year
Figure 21: Global Market by Customer End Year
Figure 22: Customer Share by Year
Figure 23: Customer Segments Growth
Figure 24: MAB Growth
Figure 25: Cytokine Growth
Figure 26: Vaccine Growth
Figure 27: Cell Based Growth
Figure 28: Inhibitor/Agonist Growth
Figure 29: Other IO Therapy Growth
Figure 30: Breast Growth
Figure 31: ColoRectal Growth
Figure 32: Cervical Growth
Figure 33: Lung Growth
Figure 34: Precancer Growth
Figure 35: Prostate Growth
Figure 36: Melanoma Growth
Figure 37: Blood Growth
Figure 38: Other Cancer Growth
Figure 39: Pharma Growth
Figure 40: Clinic Growth
Figure 41: Other Customer Growth
Figure 42: FDA Cancer Drug Approvals by Year
Figure 43: Clinical Trials for Immunotherapy by Year
Figure 44: Pie Chart of Prevalence of Cancer Treatments